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Abstract: Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major
regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer,
SOX2 is dysregulated due to overexpression associated with tumor progression and low survival
rate. Many HCC cases encounter recurrence and metastasis which might be due to CSCs and also
apoptosis. Since little is known about the expression pattern of SOX2 and apoptotic genes in HCC, we
aimed to determine the prognostic significance of SOX2, Bax, and Bcl-2 in clinicopathological features,
tumor progression, and survival rate of the HCC patients. The expression of SOX2, Bax, and Bcl-2
were evaluated using qRT-PCR in 53 formalin-fixed, paraffin-embedded tissues (FFPE) of patients
and 44 controls. Correlation of these genes was analyzed with clinicopathological features and tumor
progression. The correlationship between SOX2 expression and ALBI grade as prognostic indicators
were calculated. Survival rates were determined by Kaplan–Meier survival curves. SOX2 and
Bcl-2 were remarkably overexpressed in HCC patients compared to controls (p = 0.04 and p = 0.003,
respectively). A significant association was found for both SOX2 and Bcl-2 overexpression with
TNM staging (p = 0.02, p = 0.04) and tumor grading (p = 0.01, p = 0.003), respectively. A significant
correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival
rate (p = 0.04); however, there was no significant association between Bcl-2 and survival (p = 0.5).
Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to
evaluate prognosis and response to HCC treatment.
Keywords: SRY-box 2 (SOX2); cancer stem cell; hepatocellular carcinoma; Bcl-2; Bax
1. Introduction
Hepatocellular carcinoma (HCC) is the fifth common malignancy and the third cancer-
leading death in the world [1]. The five-year survival rate of HCC is about 7% and the
annual mortality is approximately one million worldwide. Most HCC-related deaths might
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be due to inappropriate early diagnosis, lack of effective treatment [2], or extremely aggres-
sive and metastatic phenotypes of the tumor [3]. Although conventional therapies, such as
surgical resection, chemotherapy, radiotherapy, and multimodality therapies improve the
survival rate of HCC patients, many cases encounter recurrence, intrahepatic spread, and
extrahepatic metastasis [4]. This may be due to the presence of a small population of cancer
cells with different biological characteristics, so-called cancer stem cells (CSCs). Several
lines of evidence support the existence of CSCs in HCC as well as other malignancies, such
as leukemias, glioblastomas, and breast, prostate, gastric, lung, and colon cancers [5]. Based
on the CSC hypothesis, these cells are responsible for tumor progression via self-renewal
and extensive proliferation and cause poor prognosis, resistance to treatment [6], recur-
rence, and low survival rate [7]. It has been demonstrated that CSCs and embryonic stem
cells (ESCs) share many common properties and also the same genes might be expressed
in both cells. This supports the association of stemness trait with aberrant expression of
ESC genes which may be related to specific cancers [8].
ESC genes, such as the sex-determining region Y-box 2 (SOX2), OCT4, Klf4, c-Myc,
Nanog, and Lin28, play key roles in the reprogramming of adult differentiated somatic cells
into pluripotent stem cells [6,9], where they are essential for maintaining the pluripotency
and self-renewal of embryonic stem cells [10]. Among them, SOX2, OCT4, and Nanog
are considerable regulators for pluripotency and maintaining the undifferentiated state of
cells [9].
SOX2, an intron-less gene on the long (q) arm of chromosome 3, is the main member of
the SRY-related HMG-box (SOX) gene family [3]. The products of these genes are transcrip-
tion factors that bind to DNA via their HMG domain [3,11]. SOX2 plays an eminent role in
organ development, morphogenesis, and specification of cell type in the embryonic period
via cell proliferation, regulation of self-renewal, and maintaining pluripotency [3,8,12].
In normal adults, SOX2 expression is limited to somatic stem cells of the brain, stomach,
and colon [8] via regulating neurogenesis in the developing fetal nervous system [12].
On the other hand, SOX2 is aberrantly expressed in cancer cells, particularly CSC pop-
ulation, and its overexpression is related to poor prognosis, invasion, and metastasis in
various cancers [8,13]. SOX2 overexpression has been shown in human tumors, such as
breast, ovarian, gastric, pancreatic [11], colorectal, prostate, and skin cancers, as well as
osteosarcomas and glioblastomas [9,13].
Although SOX2 expression increases the stemness degree of tumor cells [12], little
is known about the expression pattern of SOX2 in HCC. Therefore, understanding the
molecular and regulatory mechanisms associated with tumor initiation, progression, and
metastasis would have a major impact on early detection, prognosis, and development
of therapeutic strategies. There is evidence that the expression of SOX2 and SOX9 is
significantly associated with adverse prognostic factors and overall survival in HCC [14].
Specifically, an approach to indirectly silence SOX2 expression was capable of preventing
the proliferation, migration, and invasion of HepG2 cells [15].
To the best of our knowledge, this is the first report on evaluating the possible role of
SOX2 along with apoptosis genes in the development and progression of HCC. Since most
human cancers showed a failure in apoptosis [16,17], we also assessed the expression of
pro-genes and anti-apoptotic, Bax, and Bcl-2, respectively.
2. Materials and Methods
2.1. Patients and Tissue Samples
Fifty-three HCC patients and forty-four controls referred to Firoozgar Hospital, Tehran,
Iran, were enrolled in the study. Out of the 53 patients, 32 received sorafenib and 10 re-
ceived other treatment modalities, including radiofrequency (RFA), surgery, and liver
transplantation. Because of their late diagnosis, patients were mainly in advanced stages
with metastasis to various organs; however, 11 patients received no treatment due to
intolerance to drugs or death before initiation of treatment. Because of the small sample of
patients receiving treatments other than sorafenib, a five-year survival analysis was just
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performed for patients undergoing sorafenib alone. They received systemic therapy with
sorafenib (400 mg twice daily for 24 weeks) as standard systemic therapy available. HCC
was diagnosed based on the current American Association for Study of Liver Diseases
(AASLD) guidelines [18], considering the clinical and imaging findings, confirmed via
laboratory and pathological evaluations. Histological grading of tumor differentiation was
classified according to Edmondson and Steiner [19]. The TNM staging system was based
on the American Joint Committee on Cancer (AJCC) and the International Union Against
Cancer (UICC) [20]. Patients with secondary liver cancer, such as metastasis from other
malignancies, were excluded. The control group included 44 subjects who were candidates
for liver biopsy because of raised liver enzymes, abdominal pain, portal hypertension, or
hepatosplenomegaly, but finally, histopathological examinations showed no evidence of
malignancy or cirrhosis. Written informed consent was obtained from all participants and
the protocol of the study was approved by the Ethics Committee of Tehran University of
Medical Sciences (Ethics Committee Code: IR.tums.rec.1394.388). The core needle biopsy
(CNB) method was used to obtain a biopsy from liver parenchyma with portal tracts. Tissue
samples were fixed in formalin 10% to preserve vital structures and embedded in a paraffin
wax block. Formalin-fixed paraffin-embedded tissues (FFPET) were taken from all study
subjects between October 2014 and May 2016. Four to five sections of FFPE samples were
dissected with a thickness of 10 µm to enrich the tissue content for RNA isolation.
2.2. Total RNA Extraction and cDNA Synthesis
After deparaffinization of FFPE tissues, using xylene and ethanol, RNA extraction
was accomplished using RNeasy FFPE Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. DNase treatment was also performed to eliminate
genomic DNA. To evaluate the quality and quantity of extracted RNA, spectrophotometry
and electrophoresis on 1% agarose gels were used. Extracted RNA was prone to synthesize
complementary DNA (cDNA) using AccuPower®CycleScript RT Premix (dN6) kit (Bioneer,
Daejeon, South Korea) according to the manufacturer’s protocol.
2.3. Gene Expression Analysis Using qRT-PCR
Quantitative expression of SOX2, Bax, and Bcl-2 in FFPE tissues was performed
using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). The primers
were designed using Allele ID 7.5. Table 1 shows the primer sequences of target and
housekeeping genes. All tests were performed in triplicate. qRT-PCR was performed in
a 25 µL reaction volume containing: 12.5 µL SYBR Premix EX TaqII (2X) (Takara, Shiga,
Japan), 50 ng of total RNA input, and 50 nM primers. Gene amplifications were performed
using an IQ5 multicolor real-time PCR detection system (BioRad, Hercules, CA, USA).
Amplification reactions were initiated with 1 cycle at 94 ◦C for 2 min, followed by 40 cycles
of 94 ◦C for 30 s; 58 ◦C (for SOX2), 60 ◦C (for Bax and Bcl-2) for 30 s, and 72 ◦C for 45 s.
GAPDH was also used as a housekeeping gene to normalize gene expression patterns.
Relative gene expression analysis was carried out using the 2−∆∆CT method (Livak and
Schmittgen, Methods, 2001). ∆Ct values were determined by subtracting the Ct value of the
target gene (SOX2, Bax, or Bcl2) from the reference gene (GAPDH) and ∆∆Ct values were
calculated by subtracting the ∆Ct value of each HCC sample from the average ∆Ct value
of the control samples.
Table 1. Sequence of the oligonucleotide primers used in qRT-PCR.
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Statistical analyses were performed using the SPSS version 17.0 and GraphPad Prism
5 software. All data displayed a normal distribution. Quantitative variables were assessed
using independent t-test or one-way analysis of variance (ANOVA). Multivariate logistic
regression analysis was used to assess any association in the gene expression between
patients and controls by calculating odds ratios with 95% confidence intervals. The Kaplan–
Meier survival curves were used to determine the survival rate.
3. Results
3.1. Demographic and Clinical Characteristics of the Patients
A total of 97 subjects including 53 HCC patients and 44 controls were studied. The
majority of patients were males (75.47%). As shown in Table 2, there was no significant
difference in age (p = 0.06) and gender (p = 0.819) between the patients and the con-
trols. Evaluation of liver enzymes showed significant differences between the two groups
(p < 0.05). On the other hand, HCC patients had a nearly two-fold increase in AST, ALT,
and ALP compared to the controls. According to Edmondson’s grading, 35.8% of tumor
harboring patients were in grade I.
Table 2. Demographic characteristics and laboratory findings of the study population.
Parameter HCC (n = 53) Control (n = 44) p-Value
Age 55.43 ± 1.870 50.53 ± 1.709 0.06
Gender
0.819Male 40 (75.47%) 25(56.8%)
Female 13 (24.53%) 19 (43.2%)
AST a (IU/L) 197 ± 34.04 79.8 ± 41.97 0.039 *
ALT b (IU/L) 93.53 ± 17.04 41.72 ± 10.26 0.0407 *
ALP c (IU/L) 565.8 ± 107.0 264.6 ± 38.42 0.05 *
Triglyceride (mg/dL) 107.7 ± 31.0 141.8 ± 30.78 0.459
Cholesterol (mg/dL) 199.5 ± 61.87 180 ± 18.64 0.7882
HDL d (mg/dL) 41.83 ± 6.237 36.5 ± 7.762 0.6055
LDL e (mg/dL) 171.4 ± 77.95 93.67 ± 21.88 0.4877
PLT f (×1000/mm3) 172.4 ± 13.11 216.8 ± 24.11 0.0842
Quantitative variables presented as mean ± SEM. *: significance value. a: aspartate aminotransferase. b: alanine
aminotransferase. c: alkaline phosphatase. d: high-density lipoprotein. e: low-density lipoprotein. f: platelet.
TNM staging showed that 60.41% of patients were in stage I (Table 3). To better
evaluate the implication of SOX2 in the disease’s severity, we combined grade I with grade
II patients as low-grade disease, and grade III with grade IV patients as high-grade disease.
Stage I and stage II were considered early-stage diseases while stage III and stage IV were
listed as advanced stages.
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Table 3. Distribution of histological grade (A) and disease stage (B) in HCC patients.
Parameter PhaseI (%) PhaseII (%) PhaseIII (%) PhaseIV (%)
Tumor grade 35.8 35.9 20.75 7.55
Clinical stage 60.41 8.33 4.2 27.06
3.2. SOX2 Is Up-Regulated in HCC Along with Bcl-2
Using qRT-PCR, we first showed an up-regulation of the SOX2 gene in HCC. As
shown in Figure 1a, SOX2 expression was prominently higher in HCC patients than
in controls (2.50 ± 2.56 vs. 1.42 ±1.02, respectively, p = 0.04). To analyze apoptotic
activity in HCC samples, we evaluated Bax and Bcl-2 expression, as pro- and anti-apoptotic
genes, respectively, in FFPE tissues from the patients and the controls. The expression
of Bax was significantly lower in HCC patients compared to the controls (0.36 ± 0.34 vs.
1.20 ± 0.95, p = 0.001, Figure 1b), while Bcl-2 expression was higher in patients than in
controls (4.16 ± 3.44 vs. 1.27 ± 0.98, p = 0.003, Figure 1c). Moreover, a weak positive
correlation was observed between the expression of SOX2 and Bcl-2 in HCC patients
(r = 0.423, p = 0.07). However, as Figure 1f shows, there was no significant correlation
between the expression of Bax and Bcl-2 in the patients (r = −0.096, p = 0.6).




Figure 1. Relative expression of SOX2, Bax, and Bcl-2 in HCC patients and controls by 2−∆∆CT method; qRT-PCR analysis 
showed an up-regulation of SOX2 (a) as well as down-regulation of Bax (b), and up-regulation of Bcl-2 in HCC patients 
(c). There was no correlation between Bax and SOX2 expression (d), a positive correlation was found between Bcl-2 and 
SOX2 expression in patients (e). There was no correlation between Bax and Bcl-2 expression (f). 
Since hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection is the most 
important risk factor for HCC establishment, we further classified HCC patients into HBV 
or HCV positive or negative groups. As shown in Table 4, there was no significant associ-
ation between infection with HBV or HCV and the expression of SOX2, Bax, or Bcl-2 in 
HCC patients. 
  
Figur 1. Relative expression of SOX2, Bax, and Bcl- in HCC patients nd controls by 2−∆∆CT
method; qRT-PCR analysis showed an up-regulation of SOX2 (a) as well as down-regulation of Bax
(b), and up-regulation of Bcl-2 in HCC patients (c). There was no correlation between Bax and SOX2
expression (d), a positive correlation was found between Bcl-2 and SOX2 expression in patients (e).
There was no co relat on between Bax and Bcl-2 exp ession ( ).
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Since hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection is the most
important risk factor for HCC establishment, we further classified HCC patients into
HBV or HCV positive or negative groups. As shown in Table 4, there was no significant
association between infection with HBV or HCV and the expression of SOX2, Bax, or Bcl-2
in HCC patients.
Table 4. Effect of HBV-, HCV-related HCC on gene expression and liver function activity.








(n = 36) p-Value
SOX2 2.608 ± 3.049 2.751± 2.664 0.9 1.744± 1.539 2.882 ± 2.911 0.4
Bcl-2 5.703 ± 4.849 3.336 ± 2.220 0.4 6.162 ± 4.845 3.482 ± 2.649 0.1
Bax 0.284 ± 0.237 0.501 ± 0.430 0.3 0.705 ± 0.371 0.371 ± 0.380 0.2
AST a 218.3 ± 193.4 190.5 ± 205.9 0.7 238.3 ± 212.0 208.5 ± 210.4 0.5
ALT b 87.80 ± 75.71 96.65 ± 113.6 0.8 69.50 ± 34.35 97.69 ± 106.3 0.7
ALP c 696.9 ± 897.7 466.7 ± 242.0 0.7 722.2 ± 368.5 532.9 ± 654.4 0.07
AFP d 415.7 ± 427.2 140.5 ± 204.2 0.1 195.0 ± 186.5 4906 ± 21244 0.5
Survival 9.308± 6.762 9.167 ± 8.140 0.8 8.500 ± 5.802 8.962 ± 7.681 0.8
All data are presented as mean ± SD. a: aspartate aminotransferase. b: alanine aminotransferase. c: alkaline phosphatase. d: alpha-fetoprotein.
3.3. The Expression of SOX2, Bax, or Bcl-2 Correlates with Liver Enzyme Activity and AFP Levels
in HCC Patients
We examined the correlation between SOX2, Bax, or Bcl-2 expression with liver func-
tion tests (LFT), including AST, ALT, ALP, as well as alpha-fetoprotein (AFP) tumor marker.
SOX2 expression was significantly correlated with AFP (p = 0.01) and ALT (p = 0.008), while
it was not correlated with ALP and AST (Figure 2) (p < 0.05).
Furthermore, a significant positive correlation was shown between Bcl-2 expression
and both ALT (p = 0.02) and ALP (p = 0.01), while a significant negative correlation was
observed between Bax expression and AFP (p = 0.03) (Table 5).
We then explored any correlation between SOX2 expression pattern and liver function.
As Figure 2 shows the HCC patients with high expression of SOX2 had higher AST
and ALT activity compared to those with low SOX2 expression (p = 0.02 and p = 0.02,
respectively). The levels of AFP were also higher in patients with SOX2 overexpression
(p = 0.06). Moreover, as Table 4 shows, HCV-positive HCC patients had a significantly
higher ALP than HCV-negative ones (p = 0.07).
Table 5. Correlation between Bax, Bcl-2, and serum liver enzyme activity.




AST 0.1 −0.384 0.1 0.326
ALT 0.5 −0.187 0.02 * 0.486
AFP 0.03 * 0.593 0.1 0.320
ALP 0.3 −0.291 0.01 * 0.537
*: significance value.
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Figure 2. Correlation between SOX2 expression and liver function activity in HCC patients. The expression of SOX2 was 
positively correlated with ALT (a) and AFP (d). Correlation with AST and ALP was marginally significant (b,c). Expression 
of SOX2 and liver function activity in HCC patients. ALT (e), AST (f), and AFP (h) levels were significantly increased in 
high-SOX2 compared to low-SOX2 expression patients. 
Furthermore, a significant positive correlation was shown between Bcl-2 expression 
and both ALT (p = 0.02) and ALP (p = 0.01), while a significant negative correlation was 
observed between Bax expression and AFP (p = 0.03) (Table 5). 
  
Figure 2. Correlation between SOX2 expression and liver function activity in HCC patients. The expression of SOX2 was
positively correlated with ALT (a) and AFP (d). Correlation with AST and ALP was marginally significant (b,c). Expression
of SOX2 and liver function activity in HCC patients. ALT (e), AST (f), and AFP (h) levels were significantly increased in
high-SOX2 compared to low-SOX2 expression patients. There was no statistically significant association between SOX2
expression and ALP (g).
3.4. SOX2 Expression Is Correlated with Tumor Progression and Lower Survival Rate
To explore the role of SOX2 in HCC progression, the correlation of SOX2 expression
was assessed with tumor grade and disease stage. As shown in Figure 3, the expression of
SOX2 was significantly more prominent in high-grade HCC patients than in those with
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low-grade tumors (p = 0.01). Moreover, HCC patients in advanced stages had higher levels
of SOX2 expression compared to those in the early stages (p = 0.02). Therefore, SOX2
overexpression was significantly correlated with HCC progression. In line with changes
in SOX2 expression, higher expression levels of Bcl-2 were also coordinated with tumor
grade (p = 0.003) and the progression of the tumor (p = 0.04). However, we did not find any
statistically significant association between the expression of Bax and tumor grading and
HCC progression (p < 0.05).




Figure 3. Based on the Edmondson grading system, 71.6% (n = 38) of tumor samples were low grade and 28.3% (n = 15) 
were high grade. Moreover, based on the TNM staging system of the AJCC/UICC, 68.75% (n = 33) of patients were in the 
early stage and 31.25% (n = 15) were in the advanced stage of HCC. mRNA expression of both SOX2 and Bcl2 were higher 
in high-grade tumors than in low-grade ones (a,c) and also higher in tumors with advanced stages than those with early 
stages (b,d). There was not a significant difference in Bax expression between tumors with different grades or stages (e,f). 
Subsequently, to evaluate the relationship between SOX2 expression and overall sur-
vival, HCC patients undergoing sorafenib treatment were divided into two groups based 
Figure 3. Based on the Edmondson grading system, 71.6% (n = 38) of tumor samples were low grade and 28.3% (n = 15)
were high grade. Moreover, based on the TNM staging system of the AJCC/UICC, 68.75% (n = 33) of patients were in the
early stage and 31.25% (n = 15) were in the advanced st ge of HCC. mRNA expression of both SOX2 and Bcl2 were higher
in high-grade tumors than i low-grade ones (a, ) a d also higher in tumors with advanced stages than thos with early
stages (b,d). There was not a significant difference in Bax expression between tumors with different grades or stages (e,f).
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Subsequently, to evaluate the relationship between SOX2 expression and overall
survival, HCC patients undergoing sorafenib treatment were divided into two groups
based on SOX2 expression: low and high expression. The mean expression level of SOX2
in 32 patients (sorafenib-received) was considered as a cut-off point (2.431) [21].
In a prospective study, we followed 32 HCC patients who had been undergoing
sorafenib for 5 years. Out of 32 patients, 17 patients showed high expression and 15 patients
had low SOX2 expression. OS was measured from the time of diagnosis of HCC to death
or until the end of the 5-year follow-up period. As Figure 4 shows, during the follow-up
period, 19.5% of the patients were alive. Patients with high SOX2 expression had a lower 5-
year OS compared to those with low expression of SOX2 (p = 0.04). There was no significant
relationship between Bax and Bcl2 expression and OS of the patients with HCC (p < 0.05).
Analysis of the OS rate in HBV- or HCV-infected HCC showed that viral hepatitis infection
did not statistically affect the survival rate of the patients (p = 0.8). We calculated the power
of analysis using the G*Power software, and it was 0.8848983.
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Figure 4. Kaplan–Meier plot for overall survival of HCC patients using the log-rank (Mantel–Cox) test; patients with 
higher expression of SOX2 had significantly lower 5-year survival rate compared to those with lower expression of SOX2 
(log-rank: 3.082, p = 0.04). The median overall survival for low SOX2 was 10.5 months and for high SOX2 was 6.5 months. 
Figure 4. Kaplan–Meier plot for overall survival of HCC patients using the log-rank (Mantel–Cox) test; patients with higher
expression of SOX2 had significantly lower 5-year survival rate compared to those with lower expression of SOX2 (log-rank:
3.082, p = 0.04). The median overall survival for low SOX2 was 10.5 months and for high SOX2 was 6.5 months. (a), Bax
(log-rank: 0.1687, p = 0.6) and Bcl2 (log-rank: 0.3873, p = 0.5) expression was not correlated with the survival rate of HCC
patients (b,c).
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4. Discussion
This study aimed to determine the prognostic value of SOX2 in tumor progression
and survival rate of patients with HCC. We found SOX2 mRNA expression in HCC tissue
samples more than two folds higher than the normal tissue samples. Our results were
consistent with studies showing SOX2 overexpression in gastric cancer [22], lung squamous
cell carcinoma [23], gastrointestinal cancers [12], cervical cancer [24], gliomas [25], and
pancreatic carcinoma [3,26].
Our results also showed that SOX2 overexpression was significantly higher in high-
grade tumors compared to low-grade samples. Moreover, the SOX2 was up-regulated up
to 2.5 folds in advanced stages than in the early stages of the disease. These results indicate
that overexpression of SOX2 could promote oncogenic traits in HCC. The results of some
studies were in line with our study; conversely, some studies have reported conflicting
results. A decreased number of SOX2-expressing cells in primary benign and malignant
skin tumors has been shown to lead to tumor regression, which is consistent with the vital
role of SOX2 in tumor progression [27]. Moreover, a meta-analysis with 1713 patients with
breast cancer reported significant associations between SOX2 expression and increased
tumor size, high tumor histological grade, increased risk of lymph node metastasis, and
the highly aggressive triple-negative phenotype; nevertheless, no association was observed
for TNM stage [28].
Overexpression of SOX2 in MCF-7 breast cancer cells has also been shown to increase
cell proliferation and tumorigenesis by upregulating cyclin D1 and subsequently facilitating
G1/S cell cycle transition [29]. Moreover, an integrated analysis of the clinical and survival
impact of SOX2 in colorectal cancer showed that SOX2 expression was not significantly
related to clinical stage and histological grade [30].
In solid tumors, such as HCC, a minor subset of cells, called CSCs can increase the
number of differentiated cells leading to the production of tumor bulks [4]. According to
the CSC hypothesis (ability of self-renewal, multilineage differentiation), tumorigenicity
might be correlated with CSCs [4,5]. Since SOX2 is a key marker of CSCs and regulates self-
renewal and differentiation of stem cells via modifications in transcriptional, translational,
and post-translational levels [31], it is likely that SOX2 transcriptionally regulates epigenetic
alterations, such as histone deacetylation, necessary for the maintenance of self-renewal
in liver CSC [32]. This might explain the role of SOX2 in tumor progression via the
self-renewal and activation of reprogramming mechanisms of cancer cells.
SOX2 is involved in many signaling pathways such as VEGF, MAPK, Notch, P53,
Wnt, and JakSTAT, and regulates the expression of many genes, which are very important
regulators of CSCs and contribute to proliferation, migration, and invasion of cancer cells,
thereby affecting cancer progression, prognosis, and resistance to anticancer therapies [33].
As a result, SOX2 overexpression promotes and maintains the stemness of CSCs, which
confirms its role in oncogenesis and tumor progression in HCC.
There are some explanations for the contradictory results regarding the tumorigenic
role of SOX2 in different cancers. The first one is ethnic variation, as different studies have
been carried out in different ethnic groups, which may affect the results. An epigenetic
mechanism, for example DNA methylation which can regulate gene expression, could
explain racial differences in breast tumor clinical biology and outcomes. Kathleen Conway
et al. suggested that racial differences in the methylation of cancer-related genes are
detectable in both tumor cells and peripheral blood leukocytes from breast cancer cases [34]
The other explanation is the use of different/unclear cut-off values in SOX2 expression.
In other words, the cut-off point has been considered in some studies as a criterion for
defining low and high expression. For example, in one study the median may be the basis
for determining the cut-off point [21], or the mean or even positive or negative expression
of the gene may be used for this purpose.
In addition, the size of the samples in various studies affects the results of the associa-
tion between SOX2 expression and the pathological features and prognosis of HCC. Cynthia
Stretch et al., who investigated the effect of sample size on differential gene expression,
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found that this parameter affects the results of microarray analysis, resulting in unstable
gene lists and poor prediction accuracy [35]. Further studies with higher numbers of study
subjects are therefore necessary to determine the correlation between SOX2 expression and
tumor progression in HCC.
In order to obtain a clear illustration of the role of SOX2 during the progression of HCC,
we evaluated the correlation between SOX2 expression and liver functions. Interestingly, we
found a strong association between SOX2 expression and the concentrations of serum ALT,
a specific enzyme of the liver, and also of the AFP tumor marker. Increased concentrations
of ALT and AFP in HCC patients associated with SOX2 overexpression confirmed the
role of SOX2 as a biomarker for HCC progression. Such correlation indicates that SOX2
may be considered a prognostic marker for liver damage in HCC. In accordance with our
results, one study in 2019 suggested that the levels of serum AFP may effectively improve
the diagnostic performance of HCC, introducing AFP as a new simple and economic
indicator for clinics [36]. Moreover, another study in 2020 showed the superiority of AFP,
along with ALT, AST, and NLR, as a combined biomarker system for HBV-HCC diagnosis
relative to the use of each single biomarker or any other combinations in patients [37].
Further research is needed to address whether overexpression of SOX2 in HCC occurs
before that of other tumor markers, in particular of AFP. The expression of the Bcl-2 family
genes was evaluated in cancerous and normal liver tissues to investigate the correlation
of SOX2 with apoptosis in HCC. An up-regulation of Bcl-2 and a down-regulation of
Bax were found in HCC patient tissues compared to the control group. Our data were
in line with previous studies in liver cancer [38,39] and also other types of cancers, such
as prostate [40], ovarian [41], and lung cancers [42]. The expression of Bcl-2, an anti-
apoptotic gene, mimicked the trend of SOX2 changes in HCC progression, whereas Bax
expression, a pro-apoptotic gene, showed a different pattern compared to SOX2 and Bcl-2
genes. Therefore, it is likely that the overexpression of SOX2 and Bcl-2 was associated
with HCC progression. Although apoptosis is reduced in most cancers, studies in HCC
have reported contradictory results [43]. In one study, the Bcl-2/Bax ratios of the tumors
were not different between cancerous and noncancerous liver tissues and there was no
correlation between apoptosis and clinical outcomes in HCC [44]. Another study indicated
that the expression of Bcl-2 decreased, while the expression of Bax increased with the
development of liver cancer [16]. Finally, another study reported a decrease in expression
of both Bax and Bcl-2 in HCC patients compared to controls [17].
Expression of apoptotic genes including Bax and Bcl-2 may vary at different stages
of tumor development and progression, such as a hepatic lesion, proliferation/cirrhosis,
and carcinogenesis. As a result, the balance of the expression of these genes might play
a vital role in the progression of liver cancer [45]. It has been shown that the silencing of
SOX2 caused apoptosis in some lung cancer cells, but not in noncancerous cells, such as
BEAS-2B and NL-20 [42]. It has been reported that SOX2 could induce BCL2L1 expression,
which rescued the cells from apoptosis and autophagy. SOX2–BCL2L1 signaling increased
chemoresistance by maintaining mitochondrial integrity and enhancing cell survival during
cancer progression [46]. Indeed, both apoptosis and autophagy were decreased upon
SOX2 overexpression which induced BCL2L, a prosurvival regulator, and critical anti-
apoptotic protein in apoptotic and autophagic pathways [47]. This supports the idea that
SOX2 induces BCL2L1-mediated survival signaling and associates with chemotherapy
resistance [42].
Survival analysis of the two subgroups of HCC patients, including those with high
and low expression of SOX2, showed that patients with high expression of SOX2 had lower
overall survival (OS) and poor prognosis compared to those with low SOX2 expression.
In line with our results, several studies reported that SOX2 overexpression was correlated
with poor prognosis in various cancers [11,42,48]. In this regard, Saigusa et al. evaluated
the association between SOX2, CD133, and Oct4 expression, and the clinical outcomes of
patients with colorectal cancer who underwent chemoradiotherapy before surgery. They
demonstrated that increased expression levels of these genes were significantly associated
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with recurrence and poor survival rates [49]. Moreover, Lu et al. reported that patients with
high expression of SOX2 in human squamous cell lung tumors and some adenocarcinomas
had lower survival rates [50]. Han et al. also indicated that SOX2 positivity was associated
with poor disease-free survival (DFS) and recurrence-free survival (RFS) in advanced
cancer [51]. Li et al. reported the overexpression of SOX2 in the nuclei of non-small-
cell lung cancer (NSCLC) cells and suggested this gene as a promising marker in the
diagnosis and treatment of NSCLC [52]. Some meta-analyses also suggested the prognostic
significance of SOX2 and its positive association with poor survival in human cancers [53].
Javaeed et al. in a meta-analysis showed that SOX2 overexpression was associated with
shorter overall survival in patients with cancer [54]. Another meta-analysis on colorectal
cancer showed SOX2 correlation with worse survival [30].
In contrast, some studies were inconsistent with our study. For example, Kim et al.
evaluated OCT4 and SOX2 expression in cervical cancer samples which showed that
patients with higher expression of SOX2 had better OS than those with low expression [55].
This conflict might be due to the different methodologies or differences in the studies’
sample size.
As mentioned, CSCs are self-renewal and highly proliferative, thus responsible for
tumor progression, chemotherapy/radiotherapy resistance, metastasis, and recurrence [6].
Hepatic CSCs regulate a hierarchical network that involves tumor formation and they
cooperate in the metastasis and prognosis of HCC [56]. In addition, overexpression of
SOX2, a biomarker of putative CSCs [57], causes the durability of liver cancer cells and
promotes HCC progression, and thereby decreases patient survival. Therefore, targeting
CSCs has become a promising way to effectively treat cancer patients [58].
Regarding the molecular mechanisms of SOX2 in tumor invasion and metastasis,
some studies have shown that SOX2 up-regulation results in increased phosphorylation of
multiple pro-metastatic proteins, such as Src, FAK, and their downstream molecules, such
as p130-cas. Phosphorylation of p130-cas might be the result of the Src kinase activation.
The Src kinase activity is essential for SOX2-mediated adhesion and migration of cells.
In this regard, it has been shown that knockdown of the SOX2 gene could lead to reduced
phosphorylation of these proteins which would consequently increase cell adhesion to
matrigel, fibronectin, and type I collagen, but not to laminin, and would decrease cell
migration followed by increased patient survival [13].
5. Conclusions
Our results indicated the overexpression of SOX2 in HCC tumor tissues compared to
normal tissues, and that was correlated with clinical stage and histological grade which
confirms the role of CSCs in the development of HCC. Moreover, Bcl-2 was upregulated
along with SOX2 and associated with high-grade tumor as well as advanced-stage of HCC.
In addition, SOX2 overexpression was positively correlated with poor OS in HCC patients.
These suggest SOX2 as a potential novel biomarker for prognosis and diagnosis of HCC
and also as an alarm to control disease progression. Our data might also help to develop
effective targeting therapy strategies, such as the silencing of SOX2 in human HCC, which
would increase the apoptosis of CSCs in vitro and significantly suppress tumorigenicity
in vivo. However, several questions about the gene regulatory pathways remained to be
answered to disclose functional aspects of new targeted therapeutic strategies.
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